Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 122


A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW.

N Engl J Med. 2010 Aug 12;363(7):620-8. doi: 10.1056/NEJMoa1002110. Epub 2010 May 18.


Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis.

Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, Gómez-Marín O.

Lung. 2010 Apr;188(2):115-23. doi: 10.1007/s00408-009-9209-8. Epub 2009 Dec 12.


Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.

Han MK, Bach DS, Hagan PG, Yow E, Flaherty KR, Toews GB, Anstrom KJ, Martinez FJ; IPFnet Investigators.

Chest. 2013 Jun;143(6):1699-708. doi: 10.1378/chest.12-1594.


Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.

Simonneau G, Rubin LJ, Galiè N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB; PACES Study Group.

Ann Intern Med. 2008 Oct 21;149(8):521-30. Erratum in: Ann Intern Med. 2009 Sep 15;151(6):435. Ann Intern Med. 2009 Jan 6;150(1):63.


Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial.

Lederer DJ, Bartels MN, Schluger NW, Brogan F, Jellen P, Thomashow BM, Kawut SM.

COPD. 2012 Jun;9(3):268-75. doi: 10.3109/15412555.2011.651180. Epub 2012 Feb 23.


Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

Redfield MM, Chen HH, Borlaug BA, Semigran MJ, Lee KL, Lewis G, LeWinter MM, Rouleau JL, Bull DA, Mann DL, Deswal A, Stevenson LW, Givertz MM, Ofili EO, O'Connor CM, Felker GM, Goldsmith SR, Bart BA, McNulty SE, Ibarra JC, Lin G, Oh JK, Patel MR, Kim RJ, Tracy RP, Velazquez EJ, Anstrom KJ, Hernandez AF, Mascette AM, Braunwald E; RELAX Trial.

JAMA. 2013 Mar 27;309(12):1268-77. doi: 10.1001/jama.2013.2024.


Sildenafil in idiopathic pulmonary fibrosis.

Mubarak K.

N Engl J Med. 2010 Nov 25;363(22):2170; author reply 2170-1. doi: 10.1056/NEJMc1010408#SA3. No abstract available.


Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial.

Blanco I, Santos S, Gea J, Güell R, Torres F, Gimeno-Santos E, Rodriguez DA, Vilaró J, Gómez B, Roca J, Barberà JA.

Eur Respir J. 2013 Oct;42(4):982-92. doi: 10.1183/09031936.00176312. Epub 2013 Feb 21.


Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study.

Rubin LJ, Badesch DB, Fleming TR, Galiè N, Simonneau G, Ghofrani HA, Oakes M, Layton G, Serdarevic-Pehar M, McLaughlin VV, Barst RJ; SUPER-2 Study Group.

Chest. 2011 Nov;140(5):1274-83. doi: 10.1378/chest.10-0969. Epub 2011 May 5.


Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.

Keogh AM, Jabbour A, Weintraub R, Brown K, Hayward CS, Macdonald PS.

J Heart Lung Transplant. 2007 Nov;26(11):1079-83. Epub 2007 Oct 24.


The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease.

Zeng WJ, Lu XL, Xiong CM, Shan GL, Liu ZH, Ni XH, Gu Q, Zhao ZH, Li JJ, He JG; Sildenafil Therapy on Pulmonary Arterial Hypertension Associated With Different Types of Congenital Heart Disease Study Group.

Clin Cardiol. 2011 Aug;34(8):513-8. doi: 10.1002/clc.20917. Epub 2011 Jun 15.


Effect of sildenafil citrate on the male sexual experience assessed with the Sexual Experience Questionnaire: a multicenter, double-blind, placebo-controlled trial with open-label extension.

Jones LA, Klimberg IW, McMurray JG, Padula R, Tseng LJ, Stecher VJ.

J Sex Med. 2008 Aug;5(8):1955-64. doi: 10.1111/j.1743-6109.2008.00879.x. Epub 2008 Jun 28.


Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension.

Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ.

Circulation. 2007 Oct 2;116(14):1555-62. Epub 2007 Sep 4.


Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.

Swigris JJ, Streiner DL, Brown KK, Belkin A, Green KE, Wamboldt FS; IPFnet Investigators.

Respir Med. 2014 Jan;108(1):181-8. doi: 10.1016/j.rmed.2013.12.009. Epub 2013 Dec 24.


The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension.

Bharani A, Mathew V, Sahu A, Lunia B.

Indian Heart J. 2003 Jan-Feb;55(1):55-9.


A phase III, multicenter, collaborative, open-label clinical trial of sildenafil in Japanese patients with pulmonary arterial hypertension.

Satoh T, Saji T, Watanabe H, Ogawa S, Takehara K, Tanabe N, Yamada N, Yao A, Miyaji K, Nakanishi N, Suzuki Y, Fujiwara T, Kuriyama T.

Circ J. 2011;75(3):677-82. Epub 2011 Feb 4. Erratum in: Circ J. 2011 Jul;75(7):1779. Satoh, Tohru [corrected to Satoh, Toru].


Does Sildenafil produce a sustained benefit in patients with pulmonary hypertension associated with parenchymal lung and cardiac disease?

Madden BP, Sheth A, Wilde M, Ong YE.

Vascul Pharmacol. 2007 Aug-Sep;47(2-3):184-8. Epub 2007 Jun 18.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk